| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
HCA
HCA Healthcare
|
Jul 14, 2026 | BUY |
Strong Buy
+14.1% avg upside
35 analysts
|
$525.00
44.49% Upside
|
+0.0% |
|
ELV
Elevance Health
|
Jul 07, 2026 | BUY |
Strong Buy
+4.5% avg upside
32 analysts
|
$450.00
5.51% Upside
|
+1.9% |
|
HUM
Humana
|
Jul 07, 2026 | HOLD |
Buy
-13.4% avg upside
34 analysts
|
$300.00
26.34% Downside
|
+2.9% |
|
ACHC
Acadia Healthcare
|
Jul 07, 2026 | HOLD |
Strong Buy
+31.7% avg upside
17 analysts
|
— | -1.0% |
|
CVS
CVS Health
|
Jul 07, 2026 | BUY |
Strong Buy
-2.3% avg upside
39 analysts
|
$110.00
3.63% Upside
|
+1.8% |
|
CNC
Centene
|
Jul 07, 2026 | BUY |
Buy
+0.2% avg upside
29 analysts
|
$75.00
9.21% Upside
|
+3.9% |
|
MOH
Molina Healthcare
|
May 11, 2026 | HOLD |
Buy
-1.8% avg upside
26 analysts
|
$209.00
13.41% Downside
|
+30.4% |
|
HCAT
Health Catalyst
|
May 08, 2026 | HOLD |
Buy
+143.2% avg upside
15 analysts
|
$3.00
30.98% Upside
|
+50.7% |
|
DCGO
DocGo
|
May 08, 2026 | BUY |
Buy
+319.3% avg upside
7 analysts
|
$3.00
365.19% Upside
|
+5.3% |
|
POWL
Powell Industries
|
May 08, 2026 | HOLD |
Buy
-3.0% avg upside
10 analysts
|
$320.00
36.70% Upside
|
-24.9% |
|
THC
Tenet Healthcare
|
Apr 30, 2026 | BUY |
Strong Buy
+15.0% avg upside
26 analysts
|
$245.00
33.34% Upside
|
+3.7% |
|
CI
Cigna
|
Apr 30, 2026 | BUY |
Strong Buy
+14.9% avg upside
29 analysts
|
$340.00
12.03% Upside
|
+1.6% |
|
UHS
Universal Health
|
Apr 29, 2026 | HOLD |
Buy
+41.8% avg upside
22 analysts
|
$194.00
34.51% Upside
|
-14.0% |
|
TDOC
Teladoc
|
Apr 29, 2026 | BUY |
Buy
+218.6% avg upside
37 analysts
|
$10.00
7.80% Upside
|
+58.9% |
|
NNOX
Nano-X Imaging
|
Apr 20, 2026 | BUY |
Strong Buy
+774.8% avg upside
7 analysts
|
$7.00
560.43% Upside
|
-18.3% |
|
NYXH
Nyxoah
|
Mar 22, 2026 | BUY |
Strong Buy
+834.6% avg upside
12 analysts
|
$11.00
596.27% Upside
|
-7.6% |
|
SGRY
Surgery Partners
|
Mar 02, 2026 | BUY |
Strong Buy
+61.5% avg upside
18 analysts
|
$33.00
118.23% Upside
|
-4.8% |
|
PGNY
Progyny
|
Feb 27, 2026 | BUY |
Strong Buy
-6.1% avg upside
14 analysts
|
$31.00
4.23% Downside
|
+82.9% |
|
CVRX
CVRx
|
Feb 15, 2026 | BUY |
Strong Buy
+124.9% avg upside
9 analysts
|
$13.00
151.89% Upside
|
+28.9% |
|
MDXG
MiMedx Group
|
Feb 15, 2026 | BUY |
Strong Buy
+153.0% avg upside
17 analysts
|
$8.00
90.39% Upside
|
-18.6% |
|
UNH
UnitedHealth
|
Jan 28, 2026 | BUY |
Strong Buy
-0.1% avg upside
36 analysts
|
$440.00
3.50% Upside
|
+46.6% |
|
LFMD
LifeMD
|
Nov 17, 2025 | BUY |
Strong Buy
+155.3% avg upside
14 analysts
|
$15.00
232.56% Upside
|
+0.6% |
|
ACAD
ACADIA Pharmaceuticals
|
Jun 13, 2025 | BUY |
Strong Buy
+41.5% avg upside
42 analysts
|
$28.00
9.87% Upside
|
-2.9% |
|
INNV
InnovAge Holding
|
Sep 15, 2022 | HOLD |
Sell
-36.9% avg upside
12 analysts
|
$5.00
57.01% Downside
|
+48.2% |
|
AVAH
Aveanna Healthcare Holdings
|
Aug 19, 2022 | BUY |
Buy
-1.3% avg upside
17 analysts
|
$5.00
46.45% Downside
|
-14.4% |
|
DVA
DaVita
|
Aug 16, 2022 | HOLD |
Hold
-27.7% avg upside
17 analysts
|
$103.00
55.66% Downside
|
+12.2% |
|
ASTH
Astrana Health
|
Aug 05, 2022 | HOLD |
Strong Buy
+15.9% avg upside
16 analysts
|
$57.00
16.25% Upside
|
-30.8% |
|
EHC
Encompass Health
|
Nov 23, 2020 | BUY |
Strong Buy
+2.8% avg upside
22 analysts
|
$76.33
29.83% Downside
|
-19.8% |
|
SLQT
SelectQuote
|
Jun 15, 2020 | BUY |
Buy
+950.7% avg upside
16 analysts
|
$32.00
4211.56% Upside
|
-29.0% |
|
HSIC
Henry Schein
|
Nov 11, 2019 | BUY |
Buy
+0.1% avg upside
25 analysts
|
$80.00
7.90% Downside
|
-5.7% |
|
CYH
Community Health
|
Aug 07, 2019 | SELL |
Sell
+34.9% avg upside
18 analysts
|
$3.00
5.97% Downside
|
-130.8% |
|
ISRG
Intuitive Surgical
|
Oct 19, 2017 | HOLD |
Strong Buy
+36.0% avg upside
36 analysts
|
$290.00
23.64% Downside
|
+41.1% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.